Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06219278 · ClinicalTrials.gov registry record
A Retrospective Review Evaluating the Matrix Pro Applicator for Treatment of Wrinkles
A clinical trial, sponsored by Candela Corporation.
- Completed
- Registry status
- 32
- Enrollment target
NCT06219278: Completed study, sponsored by Candela Corporation.
NCT06219278 is a clinical trial that has completed, run by Candela Corporation. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06219278 has completed, sponsored by Candela Corporation.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
Study Summary
This is a retrospective chart review of data from the multi-site prospective clinical trial, "Functional Usability and Feasibility Testing of the Profound Matrix™ System (FUFT2002)" to evaluate the safety and efficacy of the Profound Matrix System Matrix Pro applicator for the treatment of wrinkles.
Primary Outcome
Improvement in the appearance of wrinkles was assessed by three (3) blinded evaluators comparing photographs taken at Baseline/Pre-treatment and at the 3-month follow-up (post final treatment). Success for an individual subject (an individual responder) was determined if at least two out of three evaluators correctly identified the post-treatment photograph by selecting the correct corresponding photograph side (left or right).
Interventions
- DEVICE Profound Matrix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2023-10-29 |
| Est. Completion | 2024-07-01 |
What the finished NCT06219278 record still lists
NCT06219278 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 32 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Profound Matrix is the first listed.
NCT06219278 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06219278 about?
NCT06219278 is a clinical study titled "A Retrospective Review Evaluating the Matrix Pro Applicator for Treatment of Wrinkles". This is a retrospective chart review of data from the multi-site prospective clinical trial, "Functional Usability and Feasibility Testing of the Profound Matrix™ System (FUFT2002)" to evaluate the safety and efficacy of the Profound Matrix System Matrix Pro applicator for the treatment of wrinkles.
What is the current status of trial NCT06219278?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2023-10-29. Estimated completion is 2024-07-01.
What interventions are being tested in trial NCT06219278?
The interventions under investigation include: Profound Matrix (DEVICE).
Who is sponsoring clinical trial NCT06219278?
This trial is sponsored by Candela Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI